The DOI matches its Crossref record; 515 of the 515 references it cites were found in a registry or an index.
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
Abstract
Human CYP1A2 is one of the major CYPs in human liver and metabolizes a number of clinical drugs (e.g., clozapine, tacrine, tizanidine, and theophylline; n > 110), a number of procarcinogens (e.g., benzo[a]pyrene and aromatic amines), and several important endogenous compounds (e.g., steroids). CYP1A2 is subject to reversible and/or irreversible inhibition by a number of drugs, natural substances, and other compounds. The CYP1A gene cluster has been mapped on to chromosome 15q24.1, with close link between CYP1A1 and 1A2 sharing a common 5'-flanking region. The human CYP1A2 gene spans almost 7.8 kb comprising seven exons and six introns and codes a 515-residue protein with a molecular mass of 58,294 Da. The recently resolved CYP1A2 structure has a relatively compact, planar active site cavity that is highly adapted for the size and shape of its substrates. The architecture of the active site of 1A2 is characterized by multiple residues on helices F and I that constitutes two parallel substrate binding platforms on either side of the cavity. A large interindividual variability in the expression and activity of CYP1A2 has been observed, which is largely caused by genetic, epigenetic and environmental factors (e.g., smoking). CYP1A2 is primarily regulated by the aromatic hydrocarbon receptor (AhR) and CYP1A2 is induced through AhR-mediated transactivation following ligand binding and nuclear translocation. Induction or inhibition of CYP1A2 may provide partial explanation for some clinical drug interactions. To date, more than 15 variant alleles and a series of subvariants of the CYP1A2 gene have been identified and some of them have been associated with altered drug clearance and response and disease susceptibility. Further studies are warranted to explore the clinical and toxicological significance of altered CYP1A2 expression and activity caused by genetic, epigenetic, and environmental factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–515 of 515
Grabar, P. B., Grabnar, I., Rozman, B., Logar, D., Tomšič, M., Šuput, D., Trdan, T., Mašič, L. P., Mrhar, A., & Dolžan, V. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027482 · Cited by 51
NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status.
Osawa, Y., Osawa, K., Miyaishi, A., Higuchi, M., Tsutou, A., Matsumura, S., Tabuchi, Y., Tsubota, N., & Takahashi, J. (2007) · PubMed · Cited by 50
Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene
Welfare, M., Aitkin, M. A., Bassendine, M. F., & Daly, A. K. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00012 · Cited by 50
Role of Glu318 at the putative distal site in the catalytic function of cytochrome P450d
Ishigooka, M., Shimizu, T., Hiroya, K., & Hatano, M. (1992) · Biochemistry · doi:10.1021/bi00120a033 · Cited by 50
In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms
Abbas, R., Chow, C. P., Browder, N., Thacker, D. L., Bramer, S. L., Fu, C. J., Forbes, W. P., Odomi, M., & Flockhart, D. A. (2000) · Human & Experimental Toxicology · doi:10.1191/096032700678827717 · Cited by 50
Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population
Hamdy, S. I., Hiratsuka, M., Narahara, K., Endo, N., El‐Enany, M. M., Moursi, N., Ahmed, M., & Mizugaki, M. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01787.x · Cited by 49
Influence of Ritonavir on Olanzapine Pharmacokinetics in Healthy Volunteers
Penzak, S. R., Hon, Y. Y., Lawhorn, W. D., Shirley, K. L., Spratlin, V. E., & Jann, M. W. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00006 · Cited by 49
Kot, M., & Daniel, W. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.12.017 · Cited by 48
Turpeinen, M., Hofmann, U., Klein, K., Mürdter, T. E., Schwab, M. G., & Zanger, U. M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025700 · Cited by 48
Niwa, T. (1999) · Xenobiotica · doi:10.1080/004982599238731 · Cited by 48
Ciprofloxacin Strongly Inhibits Clozapine Metabolism
Brouwers, E. E. M., Söhne, M., Kuipers, S., van Gorp, E. C. M., Schellens, J. H. M., Koks, C. H. W., Beijnen, J. H., & Huitema, A. D. R. (2008) · Clinical Drug Investigation · doi:10.2165/0044011-200929010-00006 · Cited by 47
Interaction of Cisapride with the Human Cytochrome P450 System: Metabolism and Inhibition Studies
Desta, Z., Soukhova, N. V., Mahal, S. K., & Flockhart, D. A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15349-4 · Cited by 47
Karjalainen, M. J., Neuvonen, P. J., & Backman, J. T. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00252.x · Cited by 47
Bapiro, T. E., Andersson, T. B., Otter, C. A., Hasler, J. A., & Masimirembwa, C. M. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0512-z · Cited by 47
Bartoli, A., Xiaodong, S., Gatti, G., Cipolla, G., Marchiselli, R., & Perucca, E. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199610000-00011 · Cited by 47
Fontaine, F. R., Delescluse, C., de Sousa, G., Lesca, P., & Rahmani, R. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00304-9 · Cited by 47
Nakano, R., Sato, H., Watanabe, A., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8570 · Cited by 47
Parkinson, A., & Hurwitz, A. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90317-e · Cited by 47
Use of 7-Ethoxycoumarin to Monitor Multiple Enzymes in the Human CYP1, CYP2, and CYP3 Families
Waxman, D. J., & Chang, T. K. H. (2006) · Humana Press eBooks · doi:10.1385/1-59259-998-2:153 · Cited by 47
Comparison of (S)‐mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms
Coller, Somogyi, & Bochner (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00005.x · Cited by 46
Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline
Dilger, K., Zheng, Z., & Klotz, U. E. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00043.x · Cited by 46
Masubuchi, Y., & Horie, T. (1999) · Chemical Research in Toxicology · doi:10.1021/tx9901276 · Cited by 46
Application of mechanism-based CYP inhibition for predicting drug–drug interactions
Zhou, Z.-W., & Zhou, S.-F. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902926099 · Cited by 46
Self-citationMachinist, J. M., Mayer, M. D., Shet, M. S., Ferrero, J. L., & Rodrigues, A. D. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06761-3 · Cited by 45
CYP2A13 Metabolizes the Substrates of Human CYP1A2, Phenacetin, and Theophylline
Fukami, T., Nakajima, M., Sakai, H., et al. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011064 · Cited by 45
CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability
Nakamura, K., Ariyoshi, N., Yokoi, T., Ohgiya, S., Chida, M., Nagashima, K., Inoue, K., Kodama, T., Shimada, N., & Kamataki, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00328-5 · Cited by 45
Backman, J. T., Schröder, M. T., & Neuvonen, P. J. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0389-y · Cited by 45
A population and family study of CYP1A2 using caffeine urinary metabolites
Catteau, A., Poisson, N., Bona�ti-Pelli�, C., Bechtel, Y. C., & Bechtel, P. R. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00196856 · Cited by 45
Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2
Kimura, S., Kawabe, M., Yu, A., Morishima, H., Fernandez-Salguero, P., Hammons, G., Ward, J. M., Kadlubar, F. F., & Gonzalez, F. J. (2003) · Carcinogenesis · doi:10.1093/carcin/24.3.583 · Cited by 45
Askmark, H., Blin, O., Drapeau, P., Meininger, V., Muir, K. W., Plaitakis, A., Umemiya, M., & Yasui, M. (1996) · Cited by 44
Ursing, C., Wikner, J., Brismar, K., & Röjdmark, S. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345194 · Cited by 43
Koutros, S., Berndt, S. I., Sinha, R. R., Ma, X., Chatterjee, N., Alavanja, M. C. R., Zheng, T., Huang, W., Hayes, R. B., & Cross, A. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2447 · Cited by 43
Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk
Mikhailova, O. N., Gulyaeva, L. F., Prudnikov, A. V., Gerasimov, A. V., & Krasilnikov, S. E. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500365 · Cited by 42
Tight-binding inhibition by α-naphthoflavone of human cytochrome P450 1A2
Cho, U., Park, E. Y., Dong, M. S., Park, B. S., Kim, K., & Kim, K. H. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/s1570-9639(03)00148-1 · Cited by 42
Furuya, H., Shimizu, T., Hatano, M., & Fujii‐Kuriyama, Y. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92485-6 · Cited by 42
Assessing human risk to heterocyclic amines
Gooderham, N. J., Murray, S., Lynch, A. M., Yadollahi‐Farsani, M., Zhao, K., Rich, K. J., Boobis, A. R., & Davies, D. S. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00025-0 · Cited by 42
Vaziri, S. A. J., Hughes, N. C., SAMPSON, H. A., Darlington, G., Jewett, M. A. S., & Grant, D. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00002 · Cited by 41
Role of cytochrome P450 1A2 in bilirubin degradation Studies in Cyp1a2 (−/−) mutant mice
Zaccaro, C., Sweitzer, S. M., Pipino, S., Gorman, N., Sinclair, P. R., Sinclair, J. F., Nebert, D. W., & Matteis, F. D. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00568-8 · Cited by 41
Backlund, M., Weidolf, L. O. G., & Ingelman‐Sundberg, M. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00225.x · Cited by 41
Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy
Takata, K., Saruwatari, J., Nakada, N., Nakagawa, M., Fukuda, K., Tanaka, F., Takenaka, S., 修一, 三., Marubayashi, T., & Nakagawa, K. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0057-z · Cited by 41
Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ
Lozano, J. J., López‐de‐Briñas, E., Centeno, N. B., Guigó, R., & Sanz, F. (1997) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1007947411145 · Cited by 40
Shimoda, K., Someya, T., Morita, S., Hirokane, G., Yokono, A., Takahashi, S., & Okawa, M. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00263-9 · Cited by 40
Pearce, R. E., Gotschall, R. R., Kearns, G. L., & Leeder, J. S. (2001) · PubMed · Cited by 40
Oganesian, A., Shilling, A. D., Young-Sciame, R., Tran, J., Watanyar, A., Azam, F., Kao, J., & Leung, L. Y. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4308 · Cited by 39
Smith, A. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.111-1241507 · Cited by 39
Theophylline metabolism: Variation and genetics
Miller, M. E., Opheim, K. E., Raisys, V. A., & Motulsky, A. G. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.23 · Cited by 39
Uroporphyrinogen oxidation catalyzed by human cytochromes P450.
Sinclair, P. R., Gorman, N., Ib, T., Fuhr, U., Walton, H. S., & Sinclair, J. F. (1998) · PubMed · Cited by 38
DICONSIGLIO, E., Meneguz, A., & Testai, E. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.009 · Cited by 38
Hilli, J., Korhonen, T., Turpeinen, M., Hokkanen, J., Mattila, S., & Laine, K. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008318669 · Cited by 38
Cheung, Y.-L., Snelling, J., Mohammed, N. N. D., Gray, T. J. B., & Ioannides, C. (1996) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.0159 · Cited by 38
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2
Kinzig‐Schippers, M., Fuhr, U., Zaigler, M., DAMMEYER, J., Rüsing, G., Labedzki, A., Bulitta, J. B., & Sörgel, F. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70105-0 · Cited by 38
Effect of Fluvoxamine on the Pharmacokinetics of Roflumilast and??Roflumilast??N-Oxide
von Richter, O., Lahu, G., Huennemeyer, A., Herzog, R., Zech, K., & Hermann, R. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746070-00006 · Cited by 36
Härtter, S., Korhonen, T., Lundgren, S., Rane, A., Tolonen, A., Turpeinen, M., & Laine, K. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_491.x · Cited by 35
Yun, C., Miller, G. P., & Guengerich, F. P. (2001) · Biochemistry · doi:10.1021/bi002906n · Cited by 35
Karjalainen, M. J., Neuvonen, P. J., & Backman, J. T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011965 · Cited by 35
Kobayashi, K., Nakajima, M., Oshima, K., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15234-8 · Cited by 34
Aitchison, K. J., Gonzalez, F. J., Quattrochi, L. C., Sapone, A., Zhao, J. H., Zaher, H., Elizondo, G., Bryant, C., Munro, J., Collier, D. A., et al. (2000) · Pharmacogenetics · doi:10.1097/00008571-200011000-00004 · Cited by 34
Murray, I. A., & Perdew, G. H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132241 · Cited by 34
FUNCTIONAL ANALYSIS OF THREE CYP1A2 VARIANTS FOUND IN A JAPANESE POPULATION
Saito, Y., Hanioka, N., Maekawa, K., Isobe, T., Tsuneto, Y., Nakamura, R., Soyama, A., Ozawa, S., Tanaka-Kagawa, T., Jinno, H., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005819 · Cited by 34
Lewis, D. F. (1999) · Experimental and Toxicologic Pathology · doi:10.1016/s0940-2993(99)80024-4 · Cited by 33
Mise, M., Hashizume, T., & Komuro, S. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022301 · Cited by 33
Effect of ciprofloxacin on the pharmacokinetics of ropivacaine
Jokinen, M. J., Olkkola, K. T., Ahonen, J., et al. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0540-8 · Cited by 32
Zheng, Y. I.-M., Henne, K. R., Charmley, P., Kim, R. B., McCarver, D. G., Cabacungan, E., Hines, R. N., & Rettie, A. E. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(02)00028-5 · Cited by 32
Stevens, C. W., Manoharan, T. H., & Fahl, W. E. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.3875 · Cited by 32
Kudo, S., Okumura, H., Miyamoto, G., & Ishizaki, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15294-4 · Cited by 32
Tay, J. K., Tan, C. H., Chong, S., & Tan, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.013 · Cited by 31
Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers
Muscat, J. E., Pittman, B. P., Kleinman, W. A., Lazarus, P. J., Stellman, S. D., & Richie, J. P. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.024 · Cited by 31
Hollingshead, B. D., Patel, R. D., & Perdew, G. H. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.029215 · Cited by 31
Pavanello, S., Simioli, P., Lupi, S., Gregorio, P., & Clonfero, E. (2002) · PubMed · Cited by 30
Pavanello, S., B’chir, F., Pulliero, A., Saguem, S., Fredj, R. B., Hayouni, A. E. A., Clonfero, E., & Mastrangelo, G. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.04.004 · Cited by 29
Petersen, M. S., Halling, J., Damkier, P., Nielsen, F., Grandjean, P., Weihe, P., & Brøsen, K. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0205-0 · Cited by 29
Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing
Skarke, C., Kirchhof, A., Geißlinger, G., & Lötsch, J. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0029-3 · Cited by 29
Koch, K. M., Corrigan, B., Manzo, J. A., James, C. D., Scott, R. J., Stead, A. G., & Kersey, K. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02031.x · Cited by 28
The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone MetabolismIn Vitro
Muschler, E., Lal, J., Jetter, A., Rattay, A., Zanger, U. M., Zadoyan, G., Fuhr, U., & Kirchheiner, J. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00457.x · Cited by 28
Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure
Lewis, D. F. V., Lake, B. G., Dickins, M., Ueng, Y., & Goldfarb, P. S. (2003) · Xenobiotica · doi:10.1080/0049825021000048791 · Cited by 28
METABOLISM OF ROFECOXIB IN VITRO USING HUMAN LIVER SUBCELLULAR FRACTIONS
Slaughter, D., Takenaga, N., Lü, P., Assang, C., Walsh, D. J., Arison, B. H., Cui, D., Halpin, R. A., Geer, L. A., Vyas, K. P., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1398 · Cited by 28
Desta, Z., Soukhova, N. V., Morocho, A. M., & Flockhart, D. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29409-x · Cited by 28
Narimatsu, S., Yonemoto, R., Saito, K., Takaya, K., Kumamoto, T., Ishikawa, T., Asanuma, M., Funada, M., Kiryu, K., Naito, S., et al. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.01.015 · Cited by 27
Larsen, J. T., & Brøsen, K. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_97365.x · Cited by 25
Mihara, K., Kondo, T., Suzuki, A., Yasui‐Furukori, N., Ono, S., Otani, K., & Kaneko, S. (2001) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2001.d01-115.x · Cited by 25
Mutlib, A. E., & Klein, J. T. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37723-7 · Cited by 25
Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes
Zhai, S., Dai, R., Wei, X., Friedman, F. K., & Vestal, R. E. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00323-3 · Cited by 24
Somers, G., Harris, A., Bayliss, M. K., & Houston, J. B. (2007) · Xenobiotica · doi:10.1080/00498250701485575 · Cited by 24
Ohmori, S., TAKEDA, S., Rikihisa, T., KIUCHI, M., Kanakubo, Y., & Kitada, M. (1993) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.16.571 · Cited by 23
Dandara, C., Basvi, P. T., Bapiro, T. E., Sayi, J., & Hasler, J. A. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.152 · Cited by 23
Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2
Labedzki, A., Buters, J., Jabrane, W., & Fuhr, U. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01019-5 · Cited by 23
Theoretical Study on the Metabolism of Caffeine by Cytochrome P‐450 1A2 and its Inhibition
Sanz, F., López‐de‐Briñas, E., Rodríguez, J., & Manaut, F. (1994) · Quantitative Structure-Activity Relationships · doi:10.1002/qsar.19940130305 · Cited by 21
Krainev, A. G., Shimizu, T., Hiroya, K., & Hatano, M. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90113-b · Cited by 21
Chen, C.-D., Doray, B., & KEMPER, B. W. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0524 · Cited by 21
Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline
Pan, P., Goldwater, Zhang, Pilmer, & Hunt (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00703.x · Cited by 21
Jensen, K. G., Poulsen, H. E., Doehmer, J., et al. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb00144.x · Cited by 19
Nassar, A.-E. F., King, I., Paris, B. L., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027516 · Cited by 19
Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS
Ajroud‐Driss, S., Saeed, M., Khan, H., Siddique, N., Hung, W.-Y., Sufit, R. L., Heller, S., Armstrong, J., Casey, P., Siddique, T., et al. (2007) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701500650 · Cited by 18
Krainev, A. G., Shimizu, T., Ishigooka, M., Hiroya, K., & Hatano, M. (1993) · Biochemistry · doi:10.1021/bi00059a011 · Cited by 17
Peters, F. T., Meyer, M. R., Theobald, D. S., & Maurer, H. H. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017293 · Cited by 17
Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers
Ko, J. M., Jang, I., SHIN, J., NAM, S., Shin, S. H., & Flockhart, D. A. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90082-6 · Cited by 16
Liang, H., McKinnon, R. A., & Nebert, D. W. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00263-3 · Cited by 16
Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo
Karjalainen, M. J., Neuvonen, P. J., & Backman, J. T. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0456-4 · Cited by 16
Hadjokas, N. E., Dai, R., Friedman, F. K., Spence, M. J., Cusack, B. J., Vestal, R. E., & Ma, Y. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704711 · Cited by 16
Zhou, S., Kestell, P., & Paxton, J. W. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120015693 · Cited by 15
Self-citationBoberg, E. W., Miller, E. C., & MILLER, J. A. (1986) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(86)80056-4 · Cited by 14
Karjalainen, M. J., Neuvonen, P. J., & Backman, J. T. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0335-z · Cited by 13
Kim, K.-B., Seo, K., Yoon, Y.-R., Bae, M. A., Cheon, H. G., Shin, J., & Liu, K. (2008) · Xenobiotica · doi:10.1080/00498250802037309 · Cited by 12
Sugahara, H., Maebara, C., Ohtani, H., Handa, M., Ando, K., Mine, K., Kubo, C., Ieiri, I., & Sawada, Y. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0629-4 · Cited by 12
Effect of alosetron on theophylline pharmacokinetics
Koch, K. M., Ricci, B., Hedayetullah, N., Jewell, D., & Kersey, K. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01477.x · Cited by 11
Yanagita, K., Sagami, I., Daff, S. N., & Shimizu, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9084 · Cited by 11
Uckun, F. M., Thoen, J. C., Chen, H., Sudbeck, E. A., Mao, C., Malaviya, R., Liu, X., & Chen, C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.1.74 · Cited by 11
Coffee, Myocardial Infarction, and CYP Nomenclature
Ingelman‐Sundberg, M., Sim, S. C., & Nebert, D. W. (2006) · JAMA · doi:10.1001/jama.296.7.764-b · Cited by 10
Kadokura, T., den Adel, M., Krauwinkel, W. J. J., Takeshige, T., & Nishida, A. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0466-x · Cited by 10
CYP1A2 is the major isoform responsible for paeonolO-demethylation in human liver microsomes
Liu, H., Hu, Y., Liu, Y., et al. (2009) · Xenobiotica · doi:10.1080/00498250902998681 · Cited by 10
Woo, S. W., Kang, T. S., Park, H. J., Lee, J.-E., & Roh, J. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.01011.x · Cited by 7
CYP1A2 F21L and F186L Polymorphisms in an Italian Population Sample
Pucci, L., Geppetti, A., Maggini, V., Lucchesi, D., Rossi, A. M., & Longo, V. G. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.220 · Cited by 6
Amyotrophic lateral sclerosis: A global threat with a possible difference in risk across ethnicities
Logroscino, G., & Armon, C. (2007) · Neurology · doi:10.1212/01.wnl.0000260229.42772.a6 · Cited by 5
Noguchi, K., Mera, A., Watanabe, T., et al. (2000) · Xenobiotica · doi:10.1080/004982500237505 · Cited by 4
Dorado, P., Berecz, R., Peñas‐Lledó, E., de la Rubia, A., & LLerena, A. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0284-6 · Cited by 3
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Due to its relatively high expression in liver, CYP1A2 plays a significant role in the metabolism of several clinically important drugs (Gunes & Dahl, 2008; Zhou et al., 2009).”
BackgroundCornelis, M. C., Monda, K. L., Yu, K., Paynter, N., Azzato, E. M., Bennett, S. N., Berndt, S. I., Boerwinkle, E., Chanock, S., Chatterjee, N., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002033 · Cited by 228
Nordestgaard, A. T., Thomsen, M., & Nordestgaard, B. G. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv083 · Cited by 189
Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice
Guo, Y., Pope, C., Cheng, X., Zhou, H., & Klaassen, C. D. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.08.058 · Cited by 77
“AhR activation and the significant induction of Cyp1a enzyme activity can increase the biotransformation of various procarcinogens and promutagens to carcinogens and mutagens that covalently bind to important functional macromolecules such as DNA, which can result in carcinogenic transformation of cells (Zhou et al.,…”
Background
Metadata
- Authors
- Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2009-12-04
- Volume
- 42
- Issue
- 2
- Pages
- 268-354
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2042005699
- Cited by
- 262
- References
- 515
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.